(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.5% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Merck & Co's revenue in 2025 is $63,922,000,000.On average, 6 Wall Street analysts forecast MRK's revenue for 2025 to be $162,591,689,243,815, with the lowest MRK revenue forecast at $161,173,052,005,058, and the highest MRK revenue forecast at $164,113,268,719,821. On average, 6 Wall Street analysts forecast MRK's revenue for 2026 to be $172,358,387,989,890, with the lowest MRK revenue forecast at $167,634,962,430,809, and the highest MRK revenue forecast at $176,792,017,943,093.
In 2027, MRK is forecast to generate $183,347,582,301,488 in revenue, with the lowest revenue forecast at $175,955,985,153,595 and the highest revenue forecast at $191,126,038,968,344.